The present invention relates to novel biologically active compounds, in particular dicarboxylic acid bisamide derivatives of general formula I:

##STR00001##

or pharmaceutically acceptable salts thereof, which are able to form complexes with or chelate metal ions. The invention also relates to the use of said compounds as an agent for the prevention and/or treatment of cardiovascular, viral, cancer, neurodegenerative and inflammatory diseases, diabetes, age-related diseases, diseases caused by microbial toxins, alcoholism and alcoholic cirrhosis, anaemia, porphyria cutanea tarda, and transition metal salt poisoning. The present invention also relates to novel methods for preparing dicarboxylic acid bisamide derivatives of general formula I.

Described herein are tetravalent binding antibody molecules comprising a FZD receptor binding domain and an LRP5/6 co-receptor binding domain on opposite termini of an Fc domain that activate a Wnt beta-catenin signaling pathway, nucleic acids and vectors encoding said molecules and methods for their use.

A pharmaceutical composition. The pharmaceutical composition comprises citric acid, paeoniflorin and gallic acid, wherein the weight ratio of citric acid, paeoniflorin and gallic acid is about 100:(1˜8):(0.1˜5). Also provided is use of the pharmaceutical composition in the treatment of rectal hemangioma and in the treatment of hemorrhoids in patients with leukemia and hemophilic.

An aortic aneurysm has few noticeable symptoms and is at high risk for rupture without a sign of abnormality. Further, if it ruptures, it causes a shock state due to massive blood loss and results in a very low survival rate. Thus, when the aortic aneurysm is found by physical examination or the like, a surgery with a stent graft or the like needs to be performed according to the state of its progression.

A pharmaceutical composition for preventing an aortic aneurysm including a medium chain fatty acid as a main component has an effect of inhibiting the occurrence and progression of the aortic aneurysm. Thus, when the aortic aneurysm is found, the composition through continuous intake can exhibit effects including inhibition of the progression of the aortic aneurysm and improvement in the vital prognosis.

An aortic aneurysm has few noticeable symptoms and is at high risk for rupture without a sign of abnormality. Further, if it ruptures, it causes a shock state due to massive blood loss and results in a very low survival rate. Thus, when the aortic aneurysm is found by physical examination or the like, a surgery with a stent graft or the like needs to be performed according to the state of its progression.

A pharmaceutical composition for preventing an aortic aneurysm including a medium chain fatty acid as a main component has an effect of inhibiting the occurrence and progression of the aortic aneurysm. Thus, when the aortic aneurysm is found, the composition through continuous intake can exhibit effects including inhibition of the progression of the aortic aneurysm and improvement in the vital prognosis.

Provided herein are novel methods and composition utilizing adipose tissue-derived stromal stem cells for treating fistulae.

The present invention provides pharmaceutical compositions comprising second-generation molecules that are superior than TOCILIZUMAB, by altering the amino acid sequences of the variable and constant regions of TOCILIZUMAB, which is a humanized anti-IL-6 receptor IgG1 antibody, to enhance the antigen-neutralizing ability and increase the pharmacokinetics, so that the therapeutic effect is exerted with a less frequency of administration, and the immunogenicity, safety and physicochemical properties (stability and homogeneity) are improved. The present invention also provides methods for producing these pharmaceutical compositions.

The present inventors have successfully generated second-generation molecules that are superior to TOCILIZUMAB by appropriately combining amino acid sequence alterations in the CDR domains, variable regions, and constant regions.

Proteins that bind IL-1α and IL-1β are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1α and IL-1β in cells, tissues, samples, and compositions.

The present application concerns methods for treating an IL-6-mediated disorder such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic JIA (sJIA), polyarticular course JIA (pcJIA), systemic sclerosis, or giant cell arteritis (GCA), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-IL-6R antibody). In particular, it relates to identification of a fixed dose of anti-IL-6R antibody, e.g. tocilizumab, which is safe and effective for subcutaneous administration in patients with IL-6-mediated disorders. In addition, formulations and devices useful for subcutaneous administration of an anti-IL-6R antibody are disclosed.

Provided herein are methods for the treatment and prevention of vascular lesions arising from RASA1 and/or EPHB4 mutations and associated with capillary malformation-arteriovenous malformation (CM-AVM).